July 28, 2006 - EXHIBIT 99.1 - 8-K: Current report filing

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com


News Release

Contact:
Patricia A. Spinella, Investor Relations 201-847-5453
Colleen T. White, Corporate Communications 201-847-5369

BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER
Reports record revenues; raises earnings guidance for full fiscal year

Franklin Lakes, NJ (July 28, 2006) BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.484 billion for the third fiscal quarter ended June 30, 2006, representing an increase of 7 percent over the prior year period. This quarters growth rate reflects an overall estimated 1 percent unfavorable impact from foreign currency translation, which affected all segments.

Our continued strong performance this quarter indicates that the strategy we are implementing is succeeding, said Edward J. Ludwig, Chairman, President and Chief Executive Officer. Strong operating performance is enabling us to make investments such as the acquisition of GeneOhm, which is performing as expected and is a key component of our strategy to reduce healthcare-associated infections. Were also increasing the pace of our R&D spending to fuel growth through innovation. Additionally, Im very pleased to announce that, once again, were raising earnings guidance for fiscal 2006.

Analysis of Third Quarter and Nine-month Period of Fiscal Year 2006 and 2005 Earnings

The following analysis of diluted earnings per share from continuing operations for the third quarter and nine-month period of fiscal 2006 and 2005 identifies specified items that affect the comparability of results between periods.


(Table 1)

	Three Months Ended June 30,							Nine Months Ended June 30,

	FY2006		FY2005		% Incr.			FY2006			FY2005			% Incr.


Diluted EPS from Continuing Operations:⁽¹⁾	$	0.81	$	0.73		11	%	$	2.26		$	2.18			4	%

Specified Items:
Insurance Settlements⁽²⁾									(0.04	)
In-Process Research and Development Charge⁽³⁾									0.21
Tax Examinations⁽⁴⁾												(0.04	)
Tax Rate Impact⁽⁵⁾				0.01								(0.02	)

				0.01					0.17			(0.06	)

Diluted EPS from Continuing Operations
Excluding Specified Items:⁽¹⁾	$	0.81	$	0.74		9	%	$	2.43		$	2.12			15	%


⁽¹⁾	Includes the effect on diluted earnings per share from continuing operations of a 2 cent reduction in the third quarter and a 3 cent reduction in the nine-month period ended June 30, 2006 relating to GeneOhm operations, which were acquired in February 2006.

⁽²⁾	Represents the effect on diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Companys previously owned latex glove business.

⁽³⁾	Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

⁽⁴⁾	Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

⁽⁵⁾	Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then-expected effective tax rate for fiscal year 2005.

As illustrated in Table 1, diluted earnings per share from continuing operations of 81 cents for the third fiscal quarter of 2006 increased by 9 percent over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005. For the nine-month period, diluted earnings per share from continuing operations, excluding specified items, of $2.43 for fiscal 2006 increased by 15 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.12 for fiscal 2005.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $828 million, representing an increase of 8 percent from the prior year period. Strong sales in the Diabetes Care unit contributed to growth. U.S. sales of safety-engineered products totaled $132 million compared with $119 million in the prior years quarter. For the nine-month period ended June 30, 2006, U.S. sales of safety-engineered products totaled $387 million compared with $360 million in the prior years period. Included in BD Medical revenues were international sales of safety-engineered products of $24 million compared with $22 million in the prior years quarter. For the nine-month period ended June 30, 2006, international sales of safety-engineered products totaled $68 million compared with $60 million in the prior years period. For the nine-month period ended June 30, 2006, the BD Medical segment reported 9 percent revenue growth over the prior year period.

In the BD Diagnostics segment, worldwide revenues for the quarter were $436 million, representing an increase of 6 percent from the prior year period. The Diagnostic Systems unit of the segment reported revenue growth of 5 percent. The Preanalytical Systems unit of the segment reported revenue growth of 7 percent. U.S. sales of safety-engineered products totaled $102 million compared with $92 million in the prior years quarter. For the nine-month period ended June 30, 2006, U.S. sales of safety-engineered products totaled $295 million compared with $258 million in the prior years period. Included in Preanalytical Systems revenues were international sales of safety-engineered products of

$60 million, compared with $52 million in the prior years quarter. For the nine-month period ended June 30, 2005, international sales of safety-engineered products totaled $167 million compared with $143 million in the prior years period. For the nine-month period ended June 30, 2006, the BD Diagnostics segment reported 5 percent revenue growth over the prior year period.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were $219 million, representing an increase of 9 percent from the prior year period. Sales of flow cytometry instruments and reagents as well as cell imaging products contributed to sales growth. For the nine-month period ended June 30, 2006, the BD Biosciences segment reported 9 percent revenue growth over the prior year period.

Geographic Results

Third quarter revenues in the U.S. were $719 million, representing an increase of 11 percent over the prior year period. Revenues outside the U.S. were $765 million, representing an increase of 5 percent over the prior year period, and reflected an estimated 1 percent unfavorable impact from foreign currency translation.

For the nine-month period ended June 30, 2006, revenues in the U.S. were $2.102 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were $2.246 billion, representing an increase of 5 percent over the prior year period, and reflected an estimated 3 percent unfavorable impact from foreign currency translation.

Fiscal 2006 Outlook for Fourth Quarter and Full Year

The following analysis of estimated diluted earnings per share from continuing operations for the fourth fiscal quarter and full fiscal year identifies specified items that affect the comparability of results between periods.


(Table 2)

	Three Months Ended September 30,						Twelve Months Ended September 30,

	FY2006		FY2005		% Incr.		FY2006			FY2005			% Incr.

	(Estimated)						(Estimated)

Diluted EPS from Continuing Operations:⁽¹⁾	$	0.83-$0.84	$	0.47	77-79	%	$	3.09-$3.10		$	2.66		16-17	%

Specified Items:
Insurance Settlements⁽²⁾								(0.04	)
In-Process Research and Development Charge⁽³⁾								0.21
Tax Examinations⁽⁴⁾											(0.04	)
Tax Rate Impact⁽⁵⁾				0.02
Repatriation Tax Charge⁽⁶⁾				0.27							0.27
Rounding											(0.01	)

				0.29				0.17			0.22

Diluted EPS from Continuing Operations Excluding Specified Items:⁽¹⁾	$	0.83-$0.84	$	0.76	9-11	%	$	3.26-$3.27		$	2.88		13-14	%


⁽¹⁾	Includes the effect on estimated diluted earnings per share from continuing operations of a 3 cent reduction in the fourth quarter and a 6 cent reduction in the twelve-month period ended September 30, 2006 relating to GeneOhm operations, which were acquired in February 2006.

⁽²⁾	Represents the effect on estimated diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Companys previously owned latex glove business.

⁽³⁾	Represents the effect on estimated diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.


⁽⁴⁾	Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

⁽⁵⁾	Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then-expected effective tax rate for fiscal year 2005.

⁽⁶⁾	Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.

As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations will increase approximately 9 to 11 percent for the fourth fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fourth fiscal quarter of 2005.

For the full fiscal year 2006, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, are expected to be in the $3.26 to $3.27 range, representing an increase of approximately 13 to 14 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.88 for the fiscal year 2005.

Conference Call Information

A conference call regarding BDs third fiscal quarter results and its expectations for the fourth fiscal quarter and full fiscal year will be broadcast live on BDs website, www.bd.com/investors, at 10:00 a.m. (ET) Friday, July 28, 2006. The conference call will be available for replay through the close of business on August 4, 2006 on BDs website, www.bd.com/investors, or at 1-888-203-1112 (domestic) and 1-719-457-0820 (international), pass code 4856925.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving peoples health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Companys capabilities are instrumental in combating many of the worlds most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled Fiscal 2006 Outlook for Fourth Quarter and Full Year, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BDs performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement

include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BDs products; fluctuations in costs and availability of raw materials and in BDs ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BDs filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BDs filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)


	Three Months Ended June 30,
	2006			2005			%Change


REVENUES	$	1,483,698		$	1,381,306			7.4

Cost of products sold		732,943			686,764			6.7
Selling and administrative		393,782			365,919			7.6
Research and development		77,967			67,003			16.4

TOTAL OPERATING COSTS AND EXPENSES		1,204,692			1,119,686			7.6


OPERATING INCOME		279,006			261,620			6.6

Interest expense		(15,425	)		(13,695	)		12.6
Interest income		12,146			10,134			19.9
Other expense, net		(2,386	)		(984	)		NM


INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		273,341			257,075			6.3

Income tax provision		66,968			67,274			(0.5	)


INCOME FROM CONTINUING OPERATIONS		206,373			189,801			8.7


LOSS FROM DISCONTINUED OPERATIONS NET OF INCOME TAX BENEFIT OF $91 IN 2005					(133	)		NM


NET INCOME	$	206,373		$	189,668			8.8


EARNINGS PER SHARE

Basic:
Income from continuing operations	$	0.84		$	0.75			12.0
Loss from discontinued operations	$			$
Net income	$	0.84		$	0.75			12.0

Diluted:
Income from continuing operations	$	0.81		$	0.73			11.0
Loss from discontinued operations	$			$
Net income	$	0.81		$	0.73			11.0



AVERAGE SHARES OUTSTANDING

Basic		246,633			251,866
Diluted		255,070			260,099


NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)


	2005

		As Reported		Tax Rate Impact (1)				Excluding Items


Income taxes		67,274			(2,059	)		65,215
effective tax rate		26.2	%					25.4	%

Income from continuing operations		189,801			2,059			191,860
as a % of revenues		13.7	%					13.9	%

Diluted earnings per share
Income from continuing operations	$	0.73		$	0.01		$	0.74


(1)	Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

Page 2

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)


	Nine Months Ended June 30,
	2006			2005			%Change


REVENUES	$	4,347,076		$	4,035,205			7.7

Cost of products sold		2,119,320			1,999,283			6.0
Selling and administrative		1,131,434			1,073,346			5.4
Research and development		276,391	(1)		195,074			41.7

TOTAL OPERATING COSTS AND EXPENSES		3,527,145			3,267,703			7.9


OPERATING INCOME		819,931			767,502			6.8

Interest expense		(51,990	)		(41,066	)		26.6
Interest income		43,808			23,827			83.9
Other expense, net		(3,999	)		(6,087	)		(34.3	)


INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		807,750			744,176			8.5

Income tax provision		227,279			173,468			31.0


INCOME FROM CONTINUING OPERATIONS		580,471			570,708			1.7

(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF $(1,330) AND $1,547, RESPECTIVELY		(2,170	) (2)		2,461			NM


NET INCOME	$	578,301		$	573,169			0.9


EARNINGS PER SHARE

Basic:
Income from continuing operations	$	2.34		$	2.26			3.5
(Loss) income from discontinued operations	$	(0.01	)	$	0.01			NM
Net income (3)	$	2.34		$	2.27			3.1

Diluted:
Income from continuing operations	$	2.26		$	2.18			3.7
(Loss) income from discontinued operations	$	(0.01	)	$	0.01			NM
Net income	$	2.25		$	2.19			2.7

AVERAGE SHARES OUTSTANDING

Basic		247,588			252,167
Diluted		256,500			261,897

NM - Not Meaningful


(1)	Includes the in-process research and development (IPR&D) charge related to the GeneOhm acquisition.

(2)	Represents certain adjustments relating to the divestiture of Clontech.

(3)	Total per share amounts may not add due to rounding.

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)


	2006

	As Reported			Insurance Settlement (1)			GeneOhm R&D (2)			Excluding Items


Selling and administrative		1,131,434			17,000						1,148,434
as a % of revenues		26.0	%								26.4	%

Research and development		276,391						(53,300	)		223,091
as a % of revenues		6.4	%								5.1	%

Operating Income		819,931			(17,000	)		53,300			856,231
as a % of revenues		18.9	%								19.7	%

Income taxes		227,279			(6,460	)					220,819
effective tax rate		28.1	%								26.2	%

Income from continuing operations		580,471			(10,540	)		53,300			623,231
as a % of revenues		13.4	%								14.3	%

Diluted earnings per share
Income from continuing operations	$	2.26		$	(0.04	)		0.21		$	2.43


(1)	Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Companys previously owned latex glove business.

(2)	Represents the in-process research and development (IPR&D) charge related to the GeneOhm acquisiton.


	2005

	As Reported			Tax Examinations (3)			Tax Rate Impact (4)			Excluding Charges


Income taxes		173,468			11,265			4,181			188,914
effective tax rate		23.3	%								25.4	%

Income from continuing operations		570,708			(11,265	)		(4,181	)		555,262
as a % of revenues		14.1	%								13.8	%

Diluted earnings per share
Income from continuing operations	$	2.18		$	(0.04	)	$	(0.02	)	$	2.12


(3)	Relates to the reversal of tax reserves in the first quarter 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(4)	Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)


	Three Months Ended June 30,
	2006		2005		% Change


BD MEDICAL
United States	$	383,030	$	338,238		13.2
International		445,439		431,980		3.1

TOTAL	$	828,469	$	770,218		7.6


BD DIAGNOSTICS
United States	$	237,817	$	218,536		8.8
International		198,596		192,207		3.3

TOTAL	$	436,413	$	410,743		6.2


BD BIOSCIENCES
United States	$	98,158	$	92,809		5.8
International		120,658		107,536		12.2

TOTAL	$	218,816	$	200,345		9.2


TOTAL REVENUES
United States	$	719,005	$	649,583		10.7
International		764,693		731,723		4.5

TOTAL	$	1,483,698	$	1,381,306		7.4

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)


	Nine Months Ended June 30,
	2006		2005		% Change


BD MEDICAL
United States	$	1,122,928	$	997,936		12.5
International		1,271,578		1,197,769		6.2

TOTAL	$	2,394,506	$	2,195,705		9.1


BD DIAGNOSTICS
United States	$	699,818	$	650,419		7.6
International		614,529		603,876		1.8

TOTAL	$	1,314,347	$	1,254,295		4.8


BD BIOSCIENCES
United States	$	278,788	$	255,453		9.1
International		359,435		329,752		9.0

TOTAL	$	638,223	$	585,205		9.1


TOTAL REVENUES
United States	$	2,101,534	$	1,903,808		10.4
International		2,245,542		2,131,397		5.4

TOTAL	$	4,347,076	$	4,035,205		7.7

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)


	United States

	2006		2005		% Change


BD MEDICAL
Medical Surgical Systems	$	230,123	$	208,818		10.2
Diabetes Care		112,432		97,006		15.9
Pharmaceutical Systems		34,612		27,034		28.0
Ophthalmic Systems		5,863		5,380		9.0

TOTAL	$	383,030	$	338,238		13.2


BD DIAGNOSTICS
Preanalytical Systems	$	131,909	$	120,283		9.7
Diagnostic Systems		105,908		98,253		7.8

TOTAL	$	237,817	$	218,536		8.8


BD BIOSCIENCES
Discovery Labware	$	31,276	$	29,374		6.5
Immunocytometry Systems		47,027		43,908		7.1
Pharmingen		19,855		19,527		1.7

TOTAL	$	98,158	$	92,809		5.8


TOTAL UNITED STATES	$	719,005	$	649,583		10.7

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)


	International

					% Change

	2006		2005		Reported		FX Neutral		FX Impact


BD MEDICAL
Medical Surgical Systems	$	217,993	$	211,676		3.0		2.5		0.5
Diabetes Care		77,660		74,309		4.5		5.3		(0.8	)
Pharmaceutical Systems		139,468		136,003		2.5		5.8		(3.3	)
Ophthalmic Systems		10,318		9,992		3.3		6.0		(2.7	)

TOTAL	$	445,439	$	431,980		3.1		4.1		(1.0	)


BD DIAGNOSTICS
Preanalytical Systems	$	107,589	$	102,543		4.9		5.7		(0.8	)
Diagnostic Systems		91,007		89,664		1.5		3.1		(1.6	)

TOTAL	$	198,596	$	192,207		3.3		4.5		(1.2	)


BD BIOSCIENCES
Discovery Labware	$	24,271	$	23,716		2.3		4.6		(2.3	)
Immunocytometry Systems		76,947		66,945		14.9		16.6		(1.7	)
Pharmingen		19,440		16,875		15.2		17.7		(2.5	)

TOTAL	$	120,658	$	107,536		12.2		14.1		(1.9	)


TOTAL INTERNATIONAL	$	764,693	$	731,723		4.5		5.7		(1.2	)

Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)


	Total

					% Change

	2006		2005		Reported		FX Neutral		FX Impact


BD MEDICAL
Medical Surgical Systems	$	448,116	$	420,494		6.6		6.3		0.3
Diabetes Care		190,092		171,315		11.0		11.3		(0.3	)
Pharmaceutical Systems		174,080		163,037		6.8		9.5		(2.7	)
Ophthalmic Systems		16,181		15,372		5.3		7.1		(1.8	)

TOTAL	$	828,469	$	770,218		7.6		8.1		(0.5	)


BD DIAGNOSTICS
Preanalytical Systems	$	239,498	$	222,826		7.5		7.8		(0.3	)
Diagnostic Systems		196,915		187,917		4.8		5.5		(0.7	)

TOTAL	$	436,413	$	410,743		6.2		6.8		(0.6	)


BD BIOSCIENCES
Discovery Labware	$	55,547	$	53,090		4.6		5.6		(1.0	)
Immunocytometry Systems		123,974		110,853		11.8		12.8		(1.0	)
Pharmingen		39,295		36,402		7.9		9.1		(1.2	)

TOTAL	$	218,816	$	200,345		9.2		10.3		(1.1	)


TOTAL REVENUES	$	1,483,698	$	1,381,306		7.4		8.0		(0.6	)

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)


	United States

	2006		2005		% Change


BD MEDICAL
Medical Surgical Systems	$	672,438	$	627,995		7.1
Diabetes Care		338,558		279,949		20.9
Pharmaceutical Systems		95,040		73,855		28.7
Ophthalmic Systems		16,892		16,137		4.7

TOTAL	$	1,122,928	$	997,936		12.5


BD DIAGNOSTICS
Preanalytical Systems	$	380,110	$	342,096		11.1
Diagnostic Systems		319,708		308,323		3.7

TOTAL	$	699,818	$	650,419		7.6


BD BIOSCIENCES
Discovery Labware	$	87,738	$	80,157		9.5
Immunocytometry Systems		133,691		119,653		11.7
Pharmingen		57,359		55,643		3.1

TOTAL	$	278,788	$	255,453		9.1


TOTAL UNITED STATES	$	2,101,534	$	1,903,808		10.4

Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)


	International

					% Change

	2006		2005		Reported			FX Neutral		FX Impact


BD MEDICAL
Medical Surgical Systems	$	628,421	$	604,355		4.0			4.1		(0.1	)
Diabetes Care		223,524		212,240		5.3			7.6		(2.3	)
Pharmaceutical Systems		389,912		352,638		10.6			16.9		(6.3	)
Ophthalmic Systems		29,721		28,536		4.2			9.0		(4.8	)

TOTAL	$	1,271,578	$	1,197,769		6.2			8.6		(2.4	)


BD DIAGNOSTICS
Preanalytical Systems	$	308,413	$	294,086		4.9			7.1		(2.2	)
Diagnostic Systems		306,116		309,790		(1.2	)		2.4		(3.6	)

TOTAL	$	614,529	$	603,876		1.8			4.7		(2.9	)


BD BIOSCIENCES
Discovery Labware	$	72,247	$	72,307		(0.1	)		4.0		(4.1	)
Immunocytometry Systems		226,709		205,060		10.6			14.4		(3.8	)
Pharmingen		60,479		52,385		15.5			20.3		(4.8	)

TOTAL	$	359,435	$	329,752		9.0			13.1		(4.1	)


TOTAL INTERNATIONAL	$	2,245,542	$	2,131,397		5.4			8.2		(2.8	)

Page 11

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)


	Total

					% Change

	2006		2005		Reported		FX Neutral		FX Impact


BD MEDICAL
Medical Surgical Systems	$	1,300,859	$	1,232,350		5.6		5.6
Diabetes Care		562,082		492,189		14.2		15.2		(1.0	)
Pharmaceutical Systems		484,952		426,493		13.7		18.9		(5.2	)
Ophthalmic Systems		46,613		44,673		4.3		7.4		(3.1	)

TOTAL	$	2,394,506	$	2,195,705		9.1		10.4		(1.3	)


BD DIAGNOSTICS
Preanalytical Systems	$	688,523	$	636,182		8.2		9.3		(1.1	)
Diagnostic Systems		625,824		618,113		1.2		3.0		(1.8	)

TOTAL	$	1,314,347	$	1,254,295		4.8		6.2		(1.4	)


BD BIOSCIENCES
Discovery Labware	$	159,985	$	152,464		4.9		6.9		(2.0	)
Immunocytometry Systems		360,400		324,713		11.0		13.4		(2.4	)
Pharmingen		117,838		108,028		9.1		11.4		(2.3	)

TOTAL	$	638,223	$	585,205		9.1		11.3		(2.2	)


TOTAL REVENUES	$	4,347,076	$	4,035,205		7.7		9.2		(1.5	)

Page 12

Form: 8-K

Documents